
usd aug pm et
summari compani develop provid research product servic analysi
genet variat function
price-to-earnings oper ep
risk assess reflect high depend
rapid technolog advanc maintain market
share impact amount custom
depend govern fund buy
product risk somewhat balanc
domin market share dna sequenc industri
sticki custom profil view
grow proport consum revenu tend
recur less volatil instrument revenu
oct ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
jul stock trade
juli surpris investor
preliminari revenu estim full
oper result yet provid
repres yoy growth
yoy quarterli revenu growth
continu deceler sinc peak
yoy slowdown
unexpect howev two year
upgrad -- launch novaseq
line dna sequenc instrument new
launch tend drive cyclic
instrument sale view
earn show materi drop
adjust pre-tax margin
led flat adjust
primari driver margin contract
sg expens grow materi
faster sale yoy
instrument sale compris
revenu averag
previou five year think lower
proport instrument sale
consum servic posit trend
instrument sale tend volatil
versu recurring-typ order consum
servic
see maintain lead
justifi premium valuat peer
neutral share howev price-to-earnings
strong long-term outlook note stock
histori rapid gain new
instrument cycl hiseq
hiseq follow sluggish
period growth expect cool may
occur sale growth recent
slow coincid two-year
anniversari novaseq launch
risk view upsid sustain
novaseq shipment growth rather
cyclic slowdown next system launch
better-than-expect growth
consum downsid risk signific
cut govern fund research lab
target ep estim
ten-year forward price-to-earnings averag
due slow growth note
growth consecut quarter versu
consecut previou upgrad
cycl like due greater competit
time around view warrant lower
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
senior vice presid
global qualiti
senior vice-president gm
middl east africa
corpor overview develop research tool large-scal analysi genet variat
function account physic differ among human eye color height
genet variat also import medic consequ includ predisposit diseas
differenti respons drug tool assist research autom billion test necessari
collect raw genet data imbed dna sequenc contain everi live cell
scientist use data investig dna sequenc dictat biolog event molecular
scale develop inform medic valuabl applic field studi known
genom rapidli expand given potenti custom diagnos treatment
improv drug therapi cure diseas
corpor strategi import aspect ilmn busi understand relationship
dna sequenc machin instrument consum instrument perman fixtur
laboratori larg up-front cost ilmn power dna sequenc machin novaseq
releas januari cost roughli million per unit convers consum
lower-cost prepar kit scientist arrang test sampl feed machin
run dna sequenc test product relationship somewhat analog razor razor blade
model lab typic purchas small number instrument continu order larg
volum consum life machin run thousand sequenc test way
singl instrument sale lead durabl long-term sale consum
last decad ilmn annual sale growth follow cyclic trend relat new instrument
launch five-quart stretch year-over-year sale growth averag coincid launch
hiseq sequenc machin hiseq launch produc five
quarter growth averag new instrument ramp though growth tend
slower expans ilmn instal base instrument field new product launch
actual reduc cyclic howev higher baselin recur consum servic demand
establish ilmn contribut sale instrument fallen
view trend favor consum carri higher margin addit lower
januari introduc novaseq system line think could reduc cost
sequenc within year note year-over-year instrument sale
fell posit growth neg june quarter howev event typic occur near
peak total sale growth expect ilmn cyclic slowdown less sever novaseq
product cycl howev due larger sale mix consum versu previou cycl
market profil signific custom concentr tool servic use
wide varieti research govern univers lab well commerci pharmaceut
biotechnolog agrigenom diagnost lab around world custom increas
util ilmn tool servic genom field rapidli develop materi
geograph composit year-over-year growth respect ilmn total sale unit state
total growth europ middl east africa total growth china
sequenc technolog continu advanc cost sequenc singl genom entir set
dna data contain cell continu fall accord nation institut cost
sequenc genom took sever week versu around sever
hour reduc time cost allow increas number entrant appli
genom market accord cb insight juli global fund genom startup
alreadi surpass record set pace doubl full-year
expect particip increasingli util sequenc tool servic effort develop
clinic commerci genom applic
competit landscap competit landscap intens sever larger
diversifi publicly-trad compani industri well numer emerg privat compani
publicly-trad compani includ thermo fisher scientif acquir main competitor life
technolog februari agil
undisput leader next gener sequenc system howev market share
estim compani sizabl instal base system like ilmn hold
competit advantag emerg compani view instal system drive
persist sale consum product util consist invest innov
also next-gen sequenc custom tend sticki transit one system anoth
costli time-consum given requir train new system integr natur
sequenc instrument laboratori work flow
financi trend sale increas compound annual growth
rate compound-annual-growth-rate mark sharp slowdown compound-annual-growth-rate three-year period
 adjust pre-tax incom per share increas compound-annual-growth-rate
conserv capit view net debt debt less cash equival
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu usd
neutral sinc juli technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
neutral fundament outlook
lst sub-industri
next year expect earn growth
remain posit slow rate achiev
posit earn growth
view strong growth public
fund medic research demand growth
emerg market expect factor
balanc slower pace
biopharmaceut spend growth
higher oper cost due tariff
budget nation institut
nih grow rapidli
academ govern lab turn
help drive sale growth mani lst
compani suppli lab nih
fy sep budget grew vs prior
year follow growth
fy fy respect growth
mark major acceler averag
fy fy believ
boost sale lst
sub-industri grew
expect lst firm
continu see strong demand
publicly-fund lab
prolifer advanc health care around
world also continu drive demand
growth lst firm trend
remain particularli strong china
emerg market rapidli grow middl
class gain access advanc health
care drive suppli need new expand
medic research lab facil
estim trend drove growth
lst sub-industri sale
asia-pacif region expect
continu posit long-term driver
contrast strong demand growth
expect publicly-fund client think
biopharmaceut firm moder
 spend growth year ahead
estim total
spend
biopharmaceut compani grew
annual averag expect slow
howev mani
biopharmaceut firm look limit spend
growth off-set recent revenu headwind
patent expir public scrutini
high drug price larg swath biopharma
 typic flow lst firm suppli
 depart research tool
softwar well contract servic
accordingli think slowdown
biopharma growth reduc tailwind
mani lst firm receiv
client group recent year
also expect recent escal trade
tariff neg impact lst earn
growth analyt
instrument maker lst sub-industri
global suppli chain see
strong oper profit growth
first half brought lower profit
mani busi think shift
relat tariff impos -china
trade septemb rais
product cost instrument maker
escal may
end sight current trade
disput expect tariff continu
pressur sale growth oper margin
sub-industri
year-to-d juli
servic rose broader
base index
five-year market price perform aug
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
analyst research note compani news
et cfra maintain hold opinion share inc
keep target price ep estim --
histor forward price-to-earnings averag due slow growth lower
ep estim revenu
grew yoy slowest quarter growth sinc growth
slow full-year yoy clip
surpris given histori lead technolog race
rapidli grow genom field wide miss consensu estim sale
growth slow sale growth led yoy drop adjust oper
incom consecut quarter declin expect growth
expect come compet dna sequenc firm improv
technolog although long-term outlook leader
rapidli grow dna sequenc field remain strong continu neutral
share howev due caution larg valuat premium
pm et cfra maintain hold opinion share inc
lower target price ep estim
line long-term histor forward price-to-earnings averag rais ep
estim present
jpmorgan health confer yesterday close report
revenu grew yoy cap cy revenu growth growth
materi slowdown yoy growth first nine month
year also forecast revenu growth rang
market reaction revenu guidanc neg share
around mid-day expect sale growth cool
impress growth howev revenu tend somewhat
cyclic new product launch novaseq system upgrad
approach two-year anniversari lower valuat multipl
think investor expect rein follow new guidanc /colin
et cfra maintain hold opinion share inc
keep price target ep
estim -- histor forward price-to-earnings averag due slow growth
lower ep estim
today announc preliminari revenu repres yoy
growth fell well short consensu estim growth
full-year revenu growth guidanc also lower
sent share approxim around mid-day
expect growth expect come compet dna
sequenc firm improv technolog recent mark
two-year anniversari latest major system upgrad
histor driven cyclic revenu long-term outlook
leader rapidli grow dna sequenc field remain strong
continu neutral share due caution forward price-to-earnings valuat
peer averag /colin scarola
et cfra maintain hold opinion share inc
lower target price
ep estim line forward price-to-earnings averag rais
ep estim initi ep vs
handili beat consensu perform quarter
impress usual sale yoy due rapid growth histori
howev mark slowdown growth rate averag yoy
prior three quarter unexpect nearli two year
remov last major tech upgrad novaseq system launch
spur recent growth acceler admir ilmn
domin posit sequenc outstand oper perform op
margin bp yoy note latest growth cycl produc sale
growth consecut quarter versu consecut last
unusu increas size warrant lower
valuat view /colin scarola
pm et cfra maintain hold opinion share inc
rais target ep estim
 histor forward price-to-earnings averag due slow growth
increas ep estim
ep vs beat consensu sale grew yoy
continu deceler recent peak quarterli sale growth
yoy declin instrument sale revenu hurt
growth consum growth yoy saw slowest pace sinc
also note materi drop adjust pre-tax margin
led flat adjust pre-tax incom yoy
despit revenu growth think rise competit dna sequenc
product contribut growth slowdown lower margin
attract growth prospect view maintain lead
burgeon sequenc market remain neutral due caution
premium valuat peer /colin scarola
et cfra maintain hold opinion share inc
lower target price ep
estim long-term averag forward price-to-earnings due slow growth
ep vs miss consensu maintain
ep estim revenu grew yoy mark
materi slowdown growth first month part
deceler relat china custom pull order
ahead tariff take effect concern us though rapidli
rise expens especi sg increas yoy
higher expens contribut yoy declin adjust pre-tax incom
full year sale growth expect slowdown around
growth novaseq upgrad cycl matur continu think
attract growth prospect maintain leadership rapidli
grow sequenc market remain neutral due caution premium
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
